The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Sorafenib in Advanced Hepatocellular Carcinoma
Open accessAbstract
BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Secondary outcomes included the time to radiologic progression and safety. RESULTS: At the second planned interim analysis, 321 deaths had occurred, and the study was stopped. Median overall survival was 10.7 months in the sorafenib group and 7.9 months in the placebo group (hazard ratio in the sorafenib group, 0.69; 95% confidence interval, 0.55 to 0.87; P<0.001). There was no significant difference between the two groups in the median time to symptomatic progression (4.1 months vs. 4.9 months, respectively, P=0.77). The median time to radiologic progression was 5.5 months in the sorafenib group and 2.8 months in the placebo group (P<0.001). Seven patients in the sorafenib group (2%) and two patients in the placebo group (1%) had a partial response; no patients had a complete response. Diarrhea, weight loss, hand-foot skin reaction, and hypophosphatemia were more frequent in the sorafenib group. CONCLUSIONS: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo. (ClinicalTrials.gov number, NCT00105443.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In previously untreated patients with advanced hepatocellular carcinoma, the approved multikinase inhibitors lenvatinib and sorafenib have provided modest median overall survival benefits of 13•6 months (lenvatinib) and 12•3 months (sorafenib).5,6”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Multikinase inhibitors, including sorafenib and lenvatinib, are first-line treatment options for patients with unresectable hepatocellular carcinoma; however, they provide modest improvements in median overall survival (ranging from 12 months to 14 months), along with unsatisfactory safety outcomes.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past two decades, the development of effective systemic therapies has substantially improved the outcomes of patients with advanced-stage HCC2–6.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The only FDA-approved drug for advanced HCC, sorafenib is well tolerated in cirrhotic patients (2) and inhibits several tyrosine kinases (e.g. VEGF, PDGFR, ERK/AKT, Ras, etc.), and their downstream oncogenic pathways (35).”
From Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib (2012) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Of note, sorafenib performed exceptionally well in patients with non-viral HCCs, with a median OS reaching 18.1 months, considerably longer than that in the SHARP trial (10.7 months) or other sorafenib arms in recent phase three trials (13–15 months), which possibly cause the lack of comparative benefits for atezolizumab-bevacizumab in this subgroup despite preserved absolute benefits [27, 32, 33]”
From Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis (2025) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,044
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,913
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Self-citationClinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R. A., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,063
Self-citationWilhelm, S. M., Carter, C., Tang, L., Wilkie, D. P., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P. W., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,060
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,725
Self-citationLlovet, J. M., Burroughs, A. K., & Bruix, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14964-1 · Cited by 3,637
Self-citationA Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,041
Self-citationRising Incidence of Hepatocellular Carcinoma in the United States
El‐Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,865
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Bisceglie, A. M. D., Bruix, J., Kramer, B. S., Lencioni, R. A., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M. T., Talwalkar, J. A., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,654
Self-citationLiu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D. P., Wilhelm, S. M., Lynch, M. J., & Carter, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1377 · Cited by 1,539
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Abou‐Alfa, G. K., Schwartz, L. H., Ricci, S., Amadori, D., Santoro, A., Figer, A., Grève, J. D., Douillard, J., Lathia, C. D., Schwartz, B. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.3441 · Cited by 1,195
Self-citationThe Liver and Portal Hypertension.
(1964) · Annals of Internal Medicine · doi:10.7326/0003-4819-61-6-1206_2 · Cited by 1,056
Ratain, M. J., Eisen, T. G., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., Gore, M. E., Desai, A. A., Patnaik, A., Xiong, H. Q., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6723 · Cited by 1,018
Zhu, A. X., Park, J. O., Ryoo, B., Yen, C.-J., Poon, R. T. P., Pastorelli, D., Blanc, J., Chung, H. C., Baron, A. D., Pfiffer, T., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00050-9 · Cited by 845
Self-citationCheng, A., Kang, Y., Lin, D., Park, J., Kudo, M., Qin, S., Chung, H. C., Song, X., Xu, J., Poggi, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8372 · Cited by 783
Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772
Self-citationUbiquitous Activation of Ras and Jak/Stat Pathways in Human HCC
Calvisi, D. F., Ladu, S., Gorden, A., Farina, M., Conner, E. A., Lee, J., Factor, V. M., & Thorgeirsson, S. S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.006 · Cited by 717
Cainap, C. I., Qin, S., Huang, W., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y., Chen, P., Toh, H.-C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 634
Llovet, J. M., Decaens, T., Raoul, J., Boucher, É., Kudo, M., Chang, C., Kang, Y., Assénat, E., Lim, H.-Y., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3009 · Cited by 595
Self-citationYeo, W., Mok, T. S. K., Zee, B. C.-Y., Leung, T. W. T., Lai, P. B. S., Lau, W. Y., Koh, J., Mo, F. K. F., Yu, S. C. H., Chan, A. T. �., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji315 · Cited by 590
Kudo, M., Imanaka, K., Chida, N., Nakachi, K., Tak, W. Y., Takayama, T., Yoon, J., Hori, T., Kumada, H., Hayashi, N., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.007 · Cited by 569
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
Zhu, A. X., Kudo, M., Assénat, E., Cattan, S., Kang, Y., Lim, H. Y., Poon, R. T. P., Blanc, J., Vogel, A., Chen, C., et al. (2014) · JAMA · doi:10.1001/jama.2014.7189 · Cited by 568
Self-citationGenomics and Signaling Pathways in Hepatocellular Carcinoma
Villanueva, A., Newell, P. H., Chiang, D. Y., Friedman, S. L., & Llovet, J. M. (2007) · Seminars in Liver Disease · doi:10.1055/s-2006-960171 · Cited by 551
Self-citationPhase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
Philip, P. A., Mahoney, M. R., Allmer, C., Thomas, J. P., Pitot, H. C., Kim, G., Donehower, R. C., Fitch, T. R., Picus, J., & Erlichman, C. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.696 · Cited by 465
Chang, Y. S., Adnane, J., Trail, P. A., Levy, J. B., Henderson, A. J., Xue, D., Bortolon, E., Ichetovkin, M., Chen, C., McNabola, A., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0393-4 · Cited by 458
Zhu, A. X., Blaszkowsky, L. S., Ryan, D. P., Clark, J. W., Muzikansky, A., Horgan, K. E., Sheehan, S., Hale, K., Enzinger, P. C., Bhargava, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9130 · Cited by 388
Angiogenesis and hepatocellular carcinoma
Semela, D., & Dufour, J. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.006 · Cited by 373
Kudo, M., Han, G., Finn, R. S., Poon, R. T. P., Blanc, J., Yan, L., Yang, J., Lu, L., Tak, W. Y., Yu, X., et al. (2014) · Hepatology · doi:10.1002/hep.27290 · Cited by 352
Self-citationIto, Y., Sasaki, Y., Horimoto, M., Wada, S., Tanaka, Y., Kasahara, A., 植木, 孝., Hirano, T., Yamamoto, H., Fujimoto, J., et al. (1998) · Hepatology · doi:10.1002/hep.510270409 · Cited by 348
LOPEZ, P. M., Villanueva, A., & Llovet, J. M. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02932.x · Cited by 343
Self-citationPhase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
Ikeda, K., Kudo, M., Kawazoe, S., Osaki, Y., Ikeda, M., Okusaka, T., Tamai, T., Suzuki, T., Hisai, T., Hayato, S., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1263-4 · Cited by 338
Transarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update
Kudo, M., Matsui, O., Izumi, N., Kadoya, M., Okusaka, T., Miyayama, S., Yamakado, K., Tsuchiya, K., Ueshima, K., Hiraoka, A., et al. (2014) · Oncology · doi:10.1159/000368142 · Cited by 283
Kudo, M., Arizumi, T., Ueshima, K., Sakurai, T., Kitano, M., & Nishida, N. (2015) · Digestive Diseases · doi:10.1159/000439290 · Cited by 226
Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trial
Lai, C., Lau, J. Y. N., Wu, P., Ngan, H., Chung, H.-T., Mitchell, S. J., Corbett, T. J., CHOW, A. W. C., & Lin, H. J. (1993) · Hepatology · doi:10.1002/hep.1840170307 · Cited by 220
Arizumi, T., Ueshima, K., Minami, T., Kono, M., Chishina, H., Takita, M., Kitai, S., Inoue, T., Yada, N., Hagiwara, S., et al. (2015) · Liver Cancer · doi:10.1159/000367743 · Cited by 207
Surgical and Locoregional Therapy of HCC: TACE
Tsurusaki, M., & Murakami, T. (2015) · Liver Cancer · doi:10.1159/000367739 · Cited by 201
Surveillance, Diagnosis, Treatment, and Outcome of Liver Cancer in Japan
Kudo, M. (2015) · Liver Cancer · doi:10.1159/000367727 · Cited by 199
Ogasawara, S., Chiba, T., Ooka, Y., Kanogawa, N., Motoyama, T., Suzuki, E., Tawada, A., Kanai, F., Yoshikawa, M., & Yokosuka, O. (2014) · Oncology · doi:10.1159/000365993 · Cited by 180
O'Dwyer, P. J., & Catalano, R. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3031 · Cited by 166
Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan
Kudo, M., Izumi, N., Sakamoto, M., Matsuyama, Y., Ichida, T., Nakashima, O., Matsui, O., Ku, Y., Kokudo, N., Makuuchi, M., et al. (2016) · Liver Cancer · doi:10.1159/000367775 · Cited by 145
Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma
Martínez-Cerezo, F. J., Tomás, A., Donoso, L., Enríquez, J., Guarner, C., Balanzó, J., Martínez‐Noguera, A., & Vilardell, F. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80138-2 · Cited by 126
O'Dwyer, P. J., Giantonio, B. J., Levy, D. E., Kauh, J. S. W., Fitzgerald, D. B., & Benson, A. B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.4143 · Cited by 106
Assessment of Patient-Reported Clinical Outcome in Pancreatic and Other Hepatobiliary Cancers
Yount, S., Cella, D. F., Webster, K., Heffernan, N., Chang, C., Odom, L., & van Gool, R. (2002) · Journal of Pain and Symptom Management · doi:10.1016/s0885-3924(02)00422-0 · Cited by 88
Faivre, S. J., Raymond, É., Douillard, J., Boucher, É., Lim, H. Y., Js, K., Lanzalone, S., Lechuga, M. J., Sherman, L. J., & Cheng, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3546 · Cited by 71
Thomas, M. B., Chadha, R., Iwasaki, M., Glover, K. Y., & Abbruzzese, J. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4567 · Cited by 61
Schwartz, J. D., Schwartz, M., Lehrer, D., Cohen, E. I., Sung, M. W., Kinkhabwala, M. M., Siegel, A. B., Holloway, S., Ocean, A. J., & Wadler, S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.4144 · Cited by 55
Self-citationA phase II study of sunitinib in patients with advanced hepatocellular carcinoma
Zhu, A. X., Sahani, D., di Tomaso, E., Duda, D. G., Sindhwani, V., Yoon, S. S., Blaszkowsky, L. S., Clark, J. W., Ryan, D. P., & Jain, R. K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4637 · Cited by 54
Locoregional Therapy for Hepatocellular Carcinoma
Obi, S., Sato, S., Kawai, T., Ichikawa, S., Ichikawa, T., Motosugi, U., Sano, K., Morisaka, H., Enomoto, N., Matsuda, M., et al. (2015) · Liver Cancer · doi:10.1159/000367741 · Cited by 54
Arizumi, T., Ueshima, K., Chishina, H., Kono, M., Takita, M., Kitai, S., Inoue, T., Yada, N., Hagiwara, S., Minami, Y., et al. (2014) · Oncology · doi:10.1159/000368143 · Cited by 53
Managing the side effects of sorafenib and sunitinib
Wood, L. S. (2006) · Community Oncology · doi:10.1016/s1548-5315(11)70751-3 · Cited by 51
Ho, M., Hasegawa, K., Chen, X., Nagano, H., Lee, Y.-J., Chau, G., Zhou, J., Wang, C.-C., Choi, Y. R., Poon, R. T. P., et al. (2016) · Liver Cancer · doi:10.1159/000449335 · Cited by 47
Bruix, J., Merle, P., Granito, A., Huang, Y., Bodoky, G., Yokosuka, O., Rosmorduc, O., Breder, V. V., Gerolami, R., Masi, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw237.03 · Cited by 40
Self-citationWhen Does the Presence of the Target Predict Response to the Targeted Agent?
Bergsland, E. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6913 · Cited by 31
Arizumi, T., Ueshima, K., Iwanishi, M., Minami, T., Chishina, H., Kono, M., Takita, M., Kitai, S., Inoue, T., Yada, N., et al. (2016) · Digestive Diseases · doi:10.1159/000448834 · Cited by 27
Finn, R. S., Merle, P., Granito, A., Huang, Y., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Gerolami, R., Caparello, C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.344 · Cited by 22
Self-citationThyroid Patient Salivary Radioiodine Transit and Dysfunction Assessment Using Chewing Gums
Okkalides, D. (2016) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2016.2076 · Cited by 6
Eskiyurt, N., Sarıdoğan, M. E., Şenel, K., Günaydın, R., Erdal, A., Akarırmak, Ü., Şendur, Ö. F., Barut, K., Akyüz, G., Özsoy, T., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-eular.5374 · Cited by 3
Flagged first, then by citations
1 of the 66 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Thomas MB, 2007, J Clin Oncol, 25, 214s
- Zhu AX, 2007, J Clin Oncol, 25, 231s
Cited by
Sorted by citations
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationManagement of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,135
Self-citationAtezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationLlovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,974
Metadata
- Authors
- Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T. F., Galle, P. R., Seitz, J.-F., Borbath, I., Häussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., & Bruix, J.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- University of Pisa (IT)
- Auckland City Hospital (NZ)
- Cliniques Universitaires Saint-Luc (BE)
- Université Européenne de Bretagne (FR)
- Centro de Investigación Biomédica en Red (ES)
- Goethe University Frankfurt (DE)
- Medizinische Hochschule Hannover (DE)
- Johannes Gutenberg University Mainz (DE)
- Aix-Marseille Université (FR)
- Bayer (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-07-24
- Volume
- 359
- Issue
- 4
- Pages
- 378-390
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1971837077
- Cited by
- 13,097
- References
- 66
- Citations by year
- 2026: 390 · 2025: 623 · 2024: 729 · 2023: 874 · 2022: 1003 · 2021: 1093 · 2020: 971 · 2019: 816 · 2018: 746 · 2017: 814 · 2016: 704 · 2015: 730 · 2014: 753 · 2013: 695 · 2012: 624
- FWCI
- 369.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Falk Foundation
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Exelixis
- Bayer HealthCare
- Eisai
- Merz Pharmaceuticals
- Ipsen
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- sorafenib, hepatocellular carcinoma, multikinase inhibitor, VEGFR, PDGFR, Raf, overall survival, adverse effects, hand-foot skin reaction, hypophosphatemia, diarrhea, weight loss
- MeSH terms
- Sorafenib, Aged, Benzenesulfonates, Double-Blind Method, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Niacinamide, Phenylurea Compounds, Pyridines, Proportional Hazards Models, Survival Analysis, Chemotherapy, Adjuvant, Disease Progression, Protein Kinase Inhibitors, raf Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
